Cheng Cameron Yin, MD, PhD

Associate Professor
Department of Hematopathology
Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA


Dr. Yin has received her MD from Beijing Medical University and her PhD from the University of Wisconsin-Madison. She is currently an Associate Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center and UT Graduate School of Biomedical Sciences. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Hematology and Molecular Genetic Pathology. In addition to clinical responsibilities on the Leukemia, Lymphoma and Molecular Diagnostic Laboratory services, Dr. Yin has been actively participating in multiple research projects in leukemia and lymphoma, which has led to over 100 research papers and over 20 Book Chapters. She serves as members of editorial boards for over 20 journals and ad hoc reviewers for over 30 Journals. Her major research interests include molecular genetic aberrations in leukemia and lymphoma, development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms, mechanisms of resistance to tyrosine kinase inhibitors in patients with chronic myelogenous leukemia, as well as the role of immunoglobulin gene rearrangement in acute myeloid leukemia.

Research Interest

Her research interests include: Molecular genetic aberrations in leukemia and lymphoma, Development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms , Mechanisms of imatinib resistance in patients with chronic myelogenous leukemia and Immunoglobulin gene rearrangement in acute myeloid leukemia.

Scientific Activities


• American Association for the Advancement of Science, (1993-1999)
• American Society for Virology, (1993-1999)
• Sigma Xi, the Scientific Research Society, (1993-Present)
• Association for Women in Science, (1995-Present)
• College of American Pathologists, (1999-Present)
• United States and Canadian Academy of Pathology, (2003-Present)
• American Society of Clinical Oncology, (2004-Present)
• American Society of Clinical Pathology, (2005-Present)
• Chinese American Pathologists Association, (2005-Present)
• American Association for Laboratory Animal Science, (2009-Present)
• American Society of Hematology, (2009-Present)
• Association for Molecular Pathology, (2009-Present)
• Society for Haematopathology/European Association for Haematopathology, (2009-Present)
• US Chinese Anti-Cancer Association, (2009-Present)
• American Association for Cancer Research, (2010-Present)
• National Association of Professional Women, (2010-Present)
• Science Advisory Board, (2010-Present)



1. Yutian Y, Baolin L, Xiangrui J, Wu R, Liou T. Cytomegalovirus (CMV) infection in cases of infantile autopsies. Chinese Journal of Pathology (Chinese). 1986; 15(2): 128-129.
2. Meihuai Y, Wu R. Mikuliczs disease with tumor-like hyperplasia of lymphoid tissue. Acta Academiae Medicinae Qingdao (Chinese). 1986; 22(1): 63-65.
3. Yutian Z, Wu R, Xiangrui J. Cytomegalovirus infection in infantile autopsies. Chinese Medical Journal. 1987; 100(9): 753-755.
4. Wu R. The immunohistochemical study of carcinoembryonic antigen in uterine carcinoma. Journal of Clinical and Experimental Pathology (Chinese). 1987; 3(4): 218-221.
5. Wu R, Jianche J, Jie S. The cyst formation in the duodenum after gastrectomy. Acta Academiae Medicinae Qingdao (Chinese). 1989; 25(4): 299
6. Wu R, Min Z, Xianlu S. The significance of CEA detection in serum and tissue of patients with gastrointestinal carcinoma. Acta Academiae Medicinae Qingdao (Chinese). 1990; 26(3): 227-230.
7. Bohua C, Wu R, Yunwen Z, et al. Experimental study of removal of sublaminar wires after spinal fixation. Chinese Journal of Surgery (Chinese). 1990; 28(7): 433-435.
8. Wu R. A study of nucleolar organizer regions in cystadenomatous neoplasm of the ovary. Acta Academiae Medicinae Qingdao (Chinese). 1991; 27(1): 50-52.
9. Wu R, Yutian Z, Xiangrui J, Cheng G, Aifeng L. Chlamydia trachomatis detection in tissues of human spontaneous abortion. Journal of Clinical and Experimental Pathology (Chinese). 1992; 8: 38-39.
10. Chen B, Hu Y, Zhou B, Wu R. Melanoma in the spinal cords. Chinese Journal of Neurosurgery (Chinese). 1993; 9(2): 65-67.
11. Wu R. The effect of tumor necrosis factor on the sensitivity of cervical carcinoma in cytotoxicity. Acta Academiae Medicinae Qingdao (Chinese). 1994; 30(3): 185-188.
12. Wu R, Coleman N, Stanley MA. The significance of IFN gamma in cytotoxicity mediated by lymphocytes to cervical keratinocytes. Chinese Journal of Microbiology and Immunology (Chinese). 1994; 14(4): 253-256.
13. Wu R, Coleman N, Stanley M. The expression of tumor necrosis factor in cervical cell lines and tissues by in situ hybridization. Chinese Journal of Obstetrics and Gynecology (Chinese). 1995; 30(11): 693-694.
14. Xiangrui J, Wu R, Xiumei Z, et al. The detection and clinical analysis of Chlamydia trachomatis infection in female genital tract. Chinese Journal of Obstetrics and Gynecology (Chinese). 1995; 30(9): 561-562.
15. Wu R, Wencui Z, Min Z, Shouyi D, Yuzhen J, Shuxian X. Detection of human papillomavirus DNA by in situ hybridization. Acta Academiae Medicinae Qingdao (Chinese). 1996; 32(3): 192-193.
16. Wu R, Coleman N, Stanley M. Differential susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity. Chinese Medical Journal. 1996; 109(11): 854-858.
17. Wu R, Stanley M, Shouyi D. The study of cytotoxicity mediated by tumor necrosis factor to cervical carcinoma derived cell lines in vitro. Journal of QiLu oncology (Chinese). 1997; 4(3): 170-172.
18. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research. 1997; 57(18): 3935-3940.
19. Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Research. 1997; 57(22): 4692-4698.
20. Wu R, Xiangrui J, Shouyi D, Zhimin W, Min Z. Expression of tumor necrosis factor mRNA, protein and receptor protein products in cervical neoplasm. Chinese Medical Journal. 1998; 111(11): 1046-1047.
21. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett B. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. American Journal of Pathology. 1999; 154(6): 1849-1855. doi: 10.1016/S0002-9440(10)65442-9
22. Wu R, Connolly D, Ren X, Fearon ER, Cho KR. Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian cancers. Neoplasia. 1999; 1(4): 311-314.
23. Wu R, Connolly D, Cho KR. Restored expression of Fragile Histidine Triad protein and tumorigenicity of cervical carcinoma cells. Journal of the National Cancer Institute. 2000; 92(4): 338-344. doi: 10.1093/jnci/92.4.338
24. Connolly D, Greenspan D, Wu R, et al. Loss of Fhit protein expression in invasive cervical carcinoma and intraepithelial lesions associated with invasive disease. Clinical Cancer Research. 2000; 6(9): 3505-3510.
25. Wu R, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene. 2000; 19(48): 5543-5546.
26. Wu R, Zhai Y, Fearon ER, and Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Research. 2001; 61(22): 8247-8255.
27. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 2002; 1(2): 145-155.
28. Leung JY, Kolligs FT, Wu R, et al. Activation of AXIN2 expression by beta-catenin/TCF: A feedback repressor pathway regulating Wnt signaling. Journal of Biological Chemistry. 2002; 277(24): 21657-21665. doi: 10.1074/jbc.M200139200
29. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research. 2002; 62(16): 4722-472.
30. Lin L, Miller CT, Contreras JI, et al. The hepatocyte nuclear factor 3 gene, HNF3 (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Research. 2002; 62(18): 5273-5279.
31. Zhai Y, Wu R, Schwartz DR, et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. American Journal of Pathology. 2002; 160(4): 1229-1238.
32. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Research. 2003; 63(11): 2913-2922.
33. Wu R, Lin L, Beer DG, Ellenson LH, et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. American Journal of Pathology. 2003; 162(5): 1603-1610. doi: 10.1016/S0002-9440(10)64294-0
34. Shedden KA, Kshirsagar MP, Schwartz DR, et al. Histologic type, organ of origin, and wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clinical Cancer Research. 2005; 11(6): 2123-2131. doi: 10.1158/1078-0432.CCR-04-2061
35. Wang YF, Wu R, Cho KR, Shedden KA, Barder TJ, Lubman DM. Classification of cancer cell lines using an automated 2-D liquid mapping method with hierarchical clustering techniques. Molecular and Cellular Proteomics. 2006; 5(1): 43-52.
36. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Research. 2006; 66(3): 1354-1362. doi: 10.1158/0008-5472.CAN-05-3694
37. Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics. 2006; 6(21): 5846-5956. doi: 10.1002/pmic.200600165
38. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007; 11(4): 321-333. doi: 10.1016/j.ccr.2007.02.016
39. Kim H, Wu R, Cho KR, et al. Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. Proteomics-Clinical Applications. 2008; 2(4): 571-584. doi: 10.1002/prca.200780004
40. Sangha N, Wu R, Kuick R, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008; 10(12): 1362-1372.
41. Wang Y, Wu R, Cho KR, et al. Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res. 2009; 3: 1452-1463.
42. Bommer GT, Feng Y, Iura A, et al. IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem. 2010; 285(3): 1928-1938. doi: 10.1074/jbc.M109.060319.
43. Zhai Y, Iura A, Yeasmin S, et al. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma. Oncogene. 2011; 30(40): 4152-4162. doi: 10.1038/onc.2011.123
44. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2011; 17(23): 7359-7372. doi: 10.1158/1078-0432.CCR-11-1388.
45. Hu PJ, Knoepp SM, Wu R, Cho KR. Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis. Genes Chromosomes Cancer. 2012; 51(3): 283-289. doi: 10.1002/gcc.20953
46. Bian C, Wu R, Cho K, Yu X. Loss of BRCA1-A complex function in RAP80 null tumor cells. PLoS One. 2012; 7(7): e40406. doi: 10.1371/journal.pone.0040406
47. Wang H, Galbán S, Wu R, et al. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2013; 19(1): 158-169. doi: 10.1158/1078-0432.CCR-12-2380
48. Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol. 2013; 182(4): 1391-1399. doi: 10.1016/j.ajpath.2012.12.031